EVALUATING THE GLYCEMIC CONTROL INDEX OF CHRONIC KIDNEY DISEASE (CKD) PATIENTS IN SOKOTO
Abstract
Diabetes is a clinical condition characterized by increased blood glucose level (hyperglycemia). Prolonged diabetes is life threatening and is one of the major risk factors of CKD. If not properly monitored could predispose an individual to a high risk of cardiovascular complication and hasten the progression of CKD to attain end stage renal disease (ESRD). As such the maintenance of glucose homeostasis is crucial in preventing pathological consequences that may result from hyperglycemia. This study therefore aims to investigate the glycemic control index of CKD patients at each stage of the disease. This study was conducted on sixty seven CKD patients attending the nephrology units of Usmanu Danfodiyo University Teaching Hospital and Specialist Hospital Sokoto. The subjects were
grouped into stages based on their estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) 4-variable equation. Blood samples were collected into lithium heparinised tubes and used to measure the glucose, glycated hemoglobin (HbA1c) and creatinine levels. The glucose level decreased from stage 1 (p > 0.05) to stage 5 while the HbA1c significantly increased as CKD advances. The HbA1c showed a highly significant negative correlation with eGFR (p = 0.0002). This study has shown there is poor glycemic control even in normoglycemic condition which could increase their progression to end stage renal disease (ESRD) and worsen the morbidity/ mortality rate among the CKD patients.
References
Akinsola A, Durosinmi MO and Akinsola NO (2009). The hematological profile of Nigerians with chronic renal failure. Afr J Med Sci, 29: 13-16.
Ansari A, Thomas S and Goldsmith D (2003). Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis, 41:523– 531.
Ardhanari S, Alpert MA and Aggarwal K (2014). Cardiovascular disease in CKD: Risk factors, Pathogenesis, and Prevention. Advances in Peritoneal dialysis, Vol 30;40-53.
Biesenbach G, Raml A, Schmekal B and Eichbaur-Strum G (2003). Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulintreated type 2 diabetic patients. Diabet Med, 20: 642-645.
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jamieson JL (2001). Diabetes mellitus. Harrison’s principle of internal Medicine, 22 (15): 2105-09.
Egbi OG, Okafor UH, Miebodei KE, Kasia BE, Kunle-Olowu OE and Unuigbe EI (2014). Prevalence and correlates of chronic kidney disease among civil Servants in Bayelsa State, Nigeria. Niger J. Clin Pract, 17: 502-507.
George A and Neilson E (2008). Disorder of the kidney and urinary tract. In: Fauci A, eds. Harrison’s principle of internal medicine. Birmingham: McGraw-Hill Professional, pp: 1741-1775.
Goldberg AP, Hagberg JM, Delmez JA, Haynes ME and Harter HR (1980). Metabolic effects of exercise training in hemodialysis patients. Kidney Int, 18:754–761.
Joy MS, Cefalu WT, Hogan SL and Nachman PH (2002). Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney, Dis 39:297–307.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Stett MW and Eknoyan G (1999). National Kidney Foundation Practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Ann Intern med, 139(2): 137-147.
Lubowsky ND, Siegel R and Pittas AG (2007). Management of glycemia in patients with diabetes mellitus and CKD. Am J kidney Dis, 50: 865-879.
Makusidi MA, Liman HM, Yakubu A, Isah MD, Jega RM, Adamu H and Chijioke A (2013). Prevalence of non-communicable diseases and its awareness among inhabitants of Sokoto metropolis: outcome of a screening program for hypertension, obesity, diabetes mellitus and overt proteinuria. Arab. J. Nephrol. Transplant, 6(3): 189-91.
Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL and Fink JC (2009). Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol, 4(6): 1121-1127.
Murray RK, Granner DK, Mayes PA and Rodwell VW (2000). Harper’s Biochemistry. A lange medical book. 25th edition. McGraw-Hill Publishers, pp: 766-767.
National Kidney Foundation-KD0Q1 (2002). Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Part 4, guideline 1. Am J Kidney Dis, 39: S1-S1000.
Odubanjo MO, Oluwasola AO and Kadiri S (2011). The epidemiology of end stage renal disease in Nigeria: The way forward. Int Urol Nephrol, 43: 785-792.
Rave K, Heise T, Pfitzner A, Heinemann L and Sawicki PT (2001). Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin type 1 diabetic patients. Diabetes Care, 24: 886-890.
Sampanis CH (2008) Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. Hippokratia, 12(1): 22-27.
Saudek CD, Derr RL and Kalvani RR (2006). Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 295(14): 1688-1697.
Seedahmed TAD and Ahmed SM (2013). Correlation between the plasma magnesium levels and glycated haemoglobin in Sudanese patients with type 2 diabetes mellitus in Khartoum State. Advances in Diabetes and metabolism, 1(1): 1-5.
Snyder RW and Bernds JS (2004). Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial, 17:365–370.
Triplitt CL (2012). Understanding the kidneys role in blood glucose regulation. Am J Manag care, 18: S11-S16.
Vijatha T, Santhi S and Jothimalar (2014). To study glycated hemoglobin level among diabetes patients with CKD not on hemodialysis. Int Journal of Medical and Applied sciences, 3(1): 136-140.
WHO (2016). Global report on diabetes. Geneva. ISBN 978 92 4 156525 7
Copyright (c) 2023 FUDMA JOURNAL OF SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
FUDMA Journal of Sciences
